Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Tofacitinib
Treatment for Ulcerative Colitis
Typical Dosage: 10 mg twice daily for induction, then 5 mg twice daily for maintenance
Effectiveness
75%
Safety Score
55%
Clinical Trials
37
Participants
3K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
10 mg twice daily for induction, then 5 mg twice daily for maintenance
Time to Effect
4-8 weeks
Treatment Duration
Long-term
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
35(Treat 35 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$42,000
Monitoring:$2,500
Side Effect Mgmt:$1,500
Total Annual:$46,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$200,000/QALY
QALYs Gained
0.6
Outcome-Based Costs
Cost per Responder
$76,666.67
Cost per Remission
$230,000
Comparison vs Biologics
Cost Difference
+$5,000/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Tofacitinib Outcomes
for Ulcerative Colitis
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+60%
Remission Rate
+20%
Common Side Effects
Nasopharyngitis
+18%
Headache
+12%
Upper respiratory tract infection
+12%
Herpes zoster
+3.5%
Serious infections
+3.5%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
10 active trials recruiting for Tofacitinib in Ulcerative Colitis
TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS
NCT06625450NOT YET RECRUITINGPHASE4
75 participants
INTERVENTIONAL
Started: Oct 1, 2024
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
NCT04624230ACTIVE NOT RECRUITINGPHASE3
118 participants
INTERVENTIONAL
Los Angeles, United States +72 more
Started: Aug 12, 2021
Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden
NCT04338204RECRUITING
120 participants
OBSERVATIONAL
Alingsås, Sweden +16 more
Started: Sep 14, 2020
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT06095128RECRUITINGPHASE4
65 participants
INTERVENTIONAL
Dothan, United States +48 more
Started: Jun 12, 2024
Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis
NCT05112263NOT YET RECRUITINGNA
96 participants
INTERVENTIONAL
Started: Jul 1, 2023
Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management
NCT04925973ACTIVE NOT RECRUITINGPHASE2
24 participants
INTERVENTIONAL
Hamilton, Canada
Started: Jun 1, 2021
Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial
NCT07297069NOT YET RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Hyderabad, India
Started: Jan 1, 2026
Prediction Model for Response to Biologics and Small Molecular Agent for UC
NCT05186623RECRUITING
300 participants
OBSERVATIONAL
Seoul, South Korea
Started: Feb 5, 2022
Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
NCT05313620RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Madrid, Spain
Started: Apr 1, 2022
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
NCT07177209ACTIVE NOT RECRUITING
4K participants
OBSERVATIONAL
Tadworth, United Kingdom
Started: Apr 1, 2026
Completed Clinical Trials
7 completed trials for Tofacitinib in Ulcerative Colitis
Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis
NCT04424303COMPLETED
152 participants
OBSERVATIONAL
Amiens, France +37 more
Started: Dec 4, 2020
Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.
NCT05728008COMPLETED
100 participants
OBSERVATIONAL
Milan, Italy
Started: Apr 5, 2022
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis
NCT01465763COMPLETEDPHASE3
614 participants
INTERVENTIONAL
Mobile, United States +177 more
Started: Apr 1, 2012
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
NCT01458951COMPLETEDPHASE3
547 participants
INTERVENTIONAL
Tucson, United States +181 more
Started: Jun 1, 2012
Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis Patients
NCT04071405COMPLETED
110 participants
OBSERVATIONAL
Seoul, South Korea
Started: May 12, 2020
Xeljanz Special Investigation for Long-term Use in UC Patients
NCT03643211COMPLETED
2.02K participants
OBSERVATIONAL
Tokyo, Japan
Started: Jun 8, 2018
This Study is to Describe and Evaluate Patients in Finland Treated With Tofacitinib for the Treatment of Ulcerative Colitis Using Real World Data.
NCT05082428COMPLETED
252 participants
OBSERVATIONAL
Helsinki, Finland
Started: May 30, 2022
Showing 20 of 38 total trials